Morimoto Masato, Takemura Hideki, Yui Takefumi, Suzuki Takahiro, Sanbe Takeyuki, Suzaki Harumi
Department of Otorhinolaryngology, Yokohama Rosai Hospital, Department of Otorhinolaryngology, Showa University.
Gan To Kagaku Ryoho. 2010 Oct;37(10):1903-6.
Several clinical trials examining treatment strategies for advanced laryngeal cancer have demonstrated that concurrent chemoradiotherapy is the most effective treatment for improving the patient response to radiotherapy and laryngeal preservation. We evaluated a new regimen of S-1/CDGP(Nedaplatin) with radiotherapy (RT), and established that it represented an effective new treatment option that allowed for the preservation of the larynx.
A total of 16 patients with stage II to IV laryngeal cancer(excluding T4 stage)who had been treated at our institution from 2001 to 2007 were recruited for the present study. All patients had histologically-confirmed squamous cell carcinomas.
The administration of S-1/CDGP/RT led to a complete response (CCR) in all patients with stage II or IV disease, with preservation of the larynx in all of these cases. For patients with stage III disease, 6 (85%) experienced CR, and 1 patient (15%) had a partial response. The laryngeal preservation rate for these patients was 85%. Severe toxicities, i. e., neutropenia, thrombocytopenia, and dermatitis of grade 3, were observed. The overall five-year survival rate was 72%, and the disease specific survival rate was 92%.
多项针对晚期喉癌治疗策略的临床试验表明，同步放化疗是提高患者放疗反应及保留喉功能的最有效治疗方法。我们评估了S-1/顺铂（奈达铂）联合放疗（RT）的新方案，并确定其为一种有效的保留喉功能的新治疗选择。
本研究纳入了2001年至2007年在我院接受治疗的16例Ⅱ至Ⅳ期喉癌患者（不包括T4期）。所有患者均经组织学确诊为鳞状细胞癌。
S-1/顺铂/放疗方案使所有Ⅱ期或Ⅳ期患者获得完全缓解（CCR），且所有这些患者均保留了喉功能。对于Ⅲ期患者，6例（85%）获得CR，1例（15%）部分缓解。这些患者的喉保留率为85%。观察到严重毒性反应，即3级中性粒细胞减少、血小板减少和皮炎。总体五年生存率为72%，疾病特异性生存率为92%。
